Efficacy and safety of adjuvant targeted therapy for patients with non-distant metastasis renal cell carcinoma
10.3760/cma.j.issn.1000-6702.2019.03.003
- VernacularTitle:无远处转移性肾癌患者术后辅助靶向治疗疗效和安全性的Meta分析
- Author:
Yu ZHENG
1
;
Di WEI
;
Guangdong HOU
;
Geng ZHANG
;
Jianlin YUAN
Author Information
1. 第四军医大学西京医院泌尿外科
- Keywords:
Renal cell carcinoma;
Targeted adjuvant therapy;
Meta-analysis
- From:
Chinese Journal of Urology
2019;40(3):171-177
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and adverse events of adjuvant targeted therapy for non-distant metastatic renal cell carcinoma (ndmRCC).Methods A comprehensive literature search was conducted in PubMed,SpringerLink,Web of Science,and the Cochrane Library.All clinical randomized controlled trials on adjuvant targeting therapy for ndmRCC were retrieved.Literature screening,data extraction and literature quality evaluation were conducted by three researchers independently,and metaanalysis was performed using Review Manager Version 5.3.Outcomes we were interested in included progression-free survival (PFS),overall survival (OS),and adverse events.Results A total of 4 RCTs with 5 studies and 4 944 ndmRCC patients were selected for meta-analysis.Targeted adjuvant therapy improved the PFS of ndmRCC patients.The hazard ratio (HR) was 0.92(95％ CI0.85-1.00,P =0.05) between the targeted therapy group and the placebo group.With the extension of follow-up,this effect was more significant,and the HR was 0.89 (95％ CI0.81-0.97,P =0.01).However,targeted adjuvant therapy did not extend the OS of ndmRCC patients,and the HR was 0.92(95％ CI0.81-1.05,P =0.22).Compared with the placebo,targeted adjuvant therapy increased the incidence of adverse events and the number of patients who had to discontinue because of adverse events was also increased.The odds ratios were 6.03 (95％ CI5.30-6.86,P ＜ 0.001) and 7.65 (95 ％ CI6.31-9.26,P ＜ 0.001),respectively.Conclusions Targeted adjuvant therapy can improve the PFS of ndmRCC patients after surgery,but it cannot improve the OS.At the same time,it increases the incidence of adverse events.
